A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.

This is a two-part single-center, open-label, parallel, single-dose pharmacokinetic study of HS-10504 in participants with hepatic impairment and normal hepatic function.

Study Overview

• Status: Not yet recruiting
• Conditions: To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function
• Intervention / Treatment: Drug: HS-10504

Detailed Description

In each part, two treatment groups were set up (Group A: participants with moderate hepatic impairment; Group B: participants with normal hepatic function), and 8 participants (both males and females) were enrolled in each group. On Day 1, a single oral dose of 400 mg HS-10504 tablet was administered in the fasting state.

• Study Type: Interventional
• Enrollment (Estimated): 32
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• All participants must meet ALL of the following criteria to be eligible for this study:

  1. Provide written informed consent before any study related procedures, have a full understanding of the study, its procedures, and possible adverse events, and express a willingness and ability to comply with the protocol requirements.
  2. Be male or female adults.
  3. Agree to practice highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of study drug (only non pharmacological contraceptive measures are allowed during the study), and refrain from attempting to conceive or donate sperm/eggs during this period.

Participants with normal hepatic function must meet the following criterion to be eligible for this study:

1. Participants in the normal hepatic function group should be matched with those in the hepatic impairment group for body mass index (BMI), age, and sex.

Participants with hepatic impairment must meet the following criteria to be eligible for this study:

1. Chronic liver injury caused by primary liver disease;
2. The investigator judges that the participant's hepatic function status is stable based on the participant's clinical symptoms and other available examination results at screening;
3. Have had a stable medication regimen for the treatment of hepatic impairment, complications, and other concomitant diseases for at least 14 days prior to administration of the investigational product, with no need for dose adjustment; or have not been on any such medication.

Exclusion Criteria:

• Participants who meet any of the following criteria will not be enrolled in this study:

  1. Have participated in any other clinical trial and used any investigational drug/device within 3 months prior to screening;
  2. Have a history of surgery within 3 months prior to screening, or have planned surgery during the study period, or have undergone surgery that may affect drug absorption, distribution, metabolism, or excretion;
  3. Have experienced significant blood loss or blood donation within 3 months prior to screening, or blood loss ≥200 mL within 1 month, or have planned blood donation during the study period;
  4. Have used strong or moderate inhibitors or inducers of CYP3A4/5, CYP2C8, and CYP2D6 within 30 days prior to the first dose of the investigational product, or have used albumin within 14 days prior to the first dose;
  5. Have a history of, or currently have, severe diseases of the nervous, psychiatric, digestive, circulatory, respiratory, urinary systems, etc., or have developed a new illness before administration of the investigational product, which is assessed by the investigator as unsuitable for participation in this study;
  6. Have a history of severe allergy, are prone to allergic reactions, or have an allergic constitution, or are known to be allergic to any component of the investigational product;
  7. Have regularly consumed alcohol within 3 months prior to screening or are unable to refrain from alcohol consumption during the study period, or have a positive alcohol breath test at screening;
  8. Have smoked an average of >5 cigarettes per day within 3 months prior to screening, or are unable to refrain from using any tobacco products during the study period;
  9. Have consumed excessive amounts of tea, coffee, and/or caffeinated beverages within 3 months prior to screening;
  10. Have a history of drug abuse, drug dependence, or illicit drug use within 5 years prior to screening, or have a positive drug abuse screening test;
  11. Are lactating women within 1 month prior to screening or during the study period, or have a positive pregnancy test;
  12. Have had unprotected sexual intercourse within 14 days prior to screening;
  13. Have special dietary requirements, are unable to comply with a uniform diet, or have difficulty swallowing;
  14. Are unable to tolerate venipuncture or indwelling needle blood sampling, or have a history of needle phobia or blood phobia;
  15. Are unable to complete the study for other reasons, or are judged by the investigator as unsuitable for participation.

Participants with normal hepatic function who meet any of the following exclusion criteria will be excluded:

1. History of hepatic impairment;
2. Clinically significant abnormalities in physical examination, vital signs, 12 lead ECG, or clinical laboratory tests at screening that are judged by the investigator as unsuitable for enrollment;
3. Use of any prescription drugs, over the counter drugs, herbal medicines, or health supplements within 14 days prior to the first dose of the investigational product, or use of any drug without a washout period of at least 7 half lives.

Participants with hepatic impairment who meet any of the following exclusion criteria will be excluded:

1. The participant has any of the following conditions that, in the investigator's assessment, makes them unsuitable for participation in this trial: ① history of liver transplantation; ② history of partial hepatectomy; ③ suspected or confirmed hepatocellular carcinoma or other malignancies; ④ hepatic failure; ⑤ bleeding from esophageal and gastric varices within 3 months prior to screening; ⑥ diseases such as biliary cirrhosis or extrahepatic biliary obstruction; ⑦ coexisting overt hepatic encephalopathy, refractory ascites, or hepatorenal syndrome.
2. Apart from the primary liver disease itself, the participant has a history of or currently has other severe systemic organ diseases or clinically significant laboratory abnormalities that, in the investigator's judgment, make them unsuitable for participation in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Participants with normal hepatic function	Drug: HS-10504; HS-10504:On Day 1, a single oral dose of 400 mg HS-10504 tablet was administered in the fasting state.
Experimental: Participants with hepatic impairment	Drug: HS-10504; HS-10504:On Day 1, a single oral dose of 400 mg HS-10504 tablet was administered in the fasting state.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of PK parameters of HS-10504: Cmax	To evaluate the Cmax of HS-10504 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504: AUC0-t	To evaluate the AUC0-t of HS-10504 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504: AUC0-∞	To evaluate the AUC0-∞ of HS-10504 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax.	To evaluate the Cmax of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-t.	To evaluate the AUC0-t of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-∞.	To evaluate the AUC0-∞ of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Tmax.	To evaluate the Tmax of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: t1/2z.	To evaluate the t1/2z of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: λz.	To evaluate the λz of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: CL/F.	To evaluate the CL/F of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Vz/F.	To evaluate the Vz/F of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: MRT0-t.	To evaluate the MRT0-t of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: MRT0-∞	To evaluate the MRT0-∞ of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: fu.	To evaluate the fu of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax,Unbound.	To evaluate the Cmax,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-t,Unbound.	To evaluate the AUC0-t,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-∞,Unbound.	To evaluate the AUC0-t,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2:CL/F,Unbound .	To evaluate the CL/F,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function	216 hours after administration of HS-10504
Adverse events	To evaluate the Occurrence of adverse events	Up to end of the study, approximately 3 months.
vital signs(blood pressure)	To evaluate the vital signs(blood pressure) of HS-10504 in participants with hepatic impairment and normal hepatic function	Up to end of the study, approximately 3 month.
vital signs( Pulse)	To evaluate the vital signs(Pulse) of HS-10504 in participants with hepatic impairment and normal hepatic function	Up to end of the study, approximately 3 month.
vital signs(body temperature)	To evaluate the vital signs( body temperature) of HS-10504 in participants with hepatic impairment and normal hepatic function	Up to end of the study, approximately 3 month.
Number of participants with clinical laboratory tests(complete blood count (CBC))	To evaluate the clinical laboratory tests(complete blood count (CBC)) of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with urinalysis	To evaluate the abnormal of urinalysis of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal blood chemistry	To evaluate the abnormal of blood chemistry of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal coagulation tests	To evaluate the abnormal of coagulation tests of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
12-lead electrocardiogram（ heart rate）	To evaluate the 12-lead electrocardiogram（heart rate） of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
12-lead electrocardiogram（PR）	To evaluate the 12-lead electrocardiogram（PR） of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
12-lead electrocardiogram（RR）	To evaluate the 12-lead electrocardiogram（RR） of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
12-lead electrocardiogram（QRS duration）	To evaluate the 12-lead electrocardiogram（QRS duration） of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
12-lead electrocardiogram（QTcF）	To evaluate the 12-lead electrocardiogram（ QTcF） of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal general inspection	To evaluate the abnormal of general inspection of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal head and neck	To evaluate the abnormal of head and neck of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal lymph nodes	To evaluate the abnormal of lymph nodes of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal chest	To evaluate the abnormal of chest of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal abdomen	To evaluate the abnormal of abdomen of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal spine and extremities	To evaluate the abnormal of spine and extremities of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.
Number of participants with abnormal neurological examination	To evaluate the abnormal of neurological examination of HS-10504 in participants with hepatic impairment and normal hepatic function.	Up to end of the study, approximately 3 month.

Collaborators and Investigators

• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): September 30, 2026
• Primary Completion (Estimated): September 25, 2027
• Study Completion (Estimated): October 30, 2027

Study Registration Dates

• First Submitted: September 11, 2026
• First Submitted That Met QC Criteria: September 22, 2026
• First Posted (Actual): September 23, 2026

Study Record Updates

• Last Update Posted (Actual): September 23, 2026
• Last Update Submitted That Met QC Criteria: September 22, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Phase I; Hepatic impairment; HS-10504
• Other Study ID Numbers: HS-10504-116

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No